PCSK9

spinqualitylabelsall models Structure of human PCSK9 catalytic domain (blue) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry 2w2m) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Function PCSK9 or Proprotein Convertase Subtilisin/Kexin type 9 is a proteinase which is part of the cholesterol synthesis. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. See details in Pro-protein convertase subtilisin/kexin type 9 (PCSK9). Relevance Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood. Inhibition of PCSK9 results in increased pathogen lipid clearance, decreased inflammatory response and improved septic shock outcome. Structural highlights PCSK9 catalytic domain interactions with LDL receptor EGF-A domain. Water molecules are shown as red spheres. PCSK9 Ca coordination site. LDL receptor Ca coordination site.

3D structures of PCSK9

Updated on 21-October-2021

Pro-protein convertase subtilisin/kexin type 9 (PCSK9), 2pmw, 2qtw – hPCSK9 – human
3bps, 2w2m, 3gcx – hPCSK9 + LDLR EGF-A
2w2n, 3gcw – hPCSK9 + LDLR EGF-A (mutant)
2w2o, 2w2p, 2w2q – hPCSK9 (mutant) + LDLR EGF-A
3h42 – hPCSK9 (mutant) + antibody
2xtj, 3sqo, 4k8r – hPCSK9 + antibody
6u2f, 6u3i – hPCSK9 + antibody + peptide inhibitor
3m0c – hPCSK9 (mutant) + LDLR
3p5b, 3p5c – hPCSK9 + LDLR variant
4ov6 – hPCSK9 + adnectin
7anq – hPCSK9 C terminal + VHH minibody

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman